2. Academic Validation
  3. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues

Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues

  • Bioorg Med Chem Lett. 2001 Sep 3;11(17):2235-9. doi: 10.1016/s0960-894x(01)00412-7.
D W Ludovici 1,  B L De Corte,  M J Kukla,  H Ye,  C Y Ho,  M A Lichtenstein,  R W Kavash,  K Andries,  M P de Béthune,  H Azijn,  R Pauwels,  P J Lewi,  J Heeres,  L M Koymans,  M R de Jonge,  K J Van Aken,  F F Daeyaert,  K Das,  E Arnold,  P A Janssen
Affiliations

Affiliation

  • 1 Janssen Research Foundation, Welsh and McKean Roads, Spring House, PA 19477, USA.
PMID: 11527705 DOI: 10.1016/s0960-894x(01)00412-7
Abstract

The synthesis and anti-HIV-1 activity of a series of diarylpyrimidines (DAPYs) are described. Several members of this novel class of non-nucleoside Reverse Transcriptase inhibitors (NNRTIs) are extremely potent against both wild-type and a panel of clinically significant single- and double-mutant strains of HIV-1.

Figures
Products